Provectus Starts Clinical PV-10 Trials for Melanoma Treatment
Peter Culpepper serves as the chief financial officer and chief operating officer of Provectus Biopharmaceuticals, a company that engineers treatments for cancer. At the beginning of 2016, Peter Culpepper’s company confirmed that the first round of human patients had received PV-10 in the phase 3 international trial of the drug. This trial will determine the efficacy of the treatment in cases of advanced cutaneous melanoma. In addition, Provectus undertook a phase 1b/2 clinical trial to look at the combination of PV-10 with an anti-PD-1 therapy manufactured by Merck called Keytruda among patient populations with stage 4 melanoma. In both trials, effectiveness will be gauged by progression-free survival (PFS) comparisons using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. PFS measurements will be taken every 12 weeks for up to 18 months. Researchers will also look at complete response rate and overall survival data. The phase 3 trial currently has seven enrollment sites across the United States and one in Australia, and Provectus plans to continue recruiting.












